## Manuel Ramos-Casals

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/339579/manuel-ramos-casals-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128 76 19,497 324 h-index g-index citations papers 6.57 382 23,566 4.9 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
324	Addressing the clinical unmet needs in primary Sjgren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts <i>Computational and Structural Biotechnology Journal</i> , <b>2022</b> , 20, 471-484	6.8	О
323	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	6
322	Gene Variation at Immunomodulatory and Cell Adhesion Molecules Loci Impacts Primary Sj\( \bar{g}\)ren's Syndrome Frontiers in Medicine, 2022, 9, 822290	4.9	
321	SARS-CoV-2 infection in patients with primary Sjören syndrome: characterization and outcomes of 51 patients. <i>Rheumatology</i> , <b>2021</b> , 60, 2946-2957	3.9	8
320	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	4
319	Mise Jour des recommandations EULAR sur l'Itilisation des thEapies immunomodulatrices dans la prise en charge de la Covid-19. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2021</b> , 88, A214-A215	0.1	
318	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	5
317	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
316	Long Covid-19: Proposed Primary Care Clinical Guidelines for Diagnosis and Disease Management. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	27
315	Systemic and organ-specific immune-related manifestations of COVID-19. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 315-332	8.1	67
314	Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. <i>Immunotherapy</i> , <b>2021</b> , 13, 465-475	3.8	2
313	Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. <i>Viruses</i> , <b>2021</b> , 13,	6.2	4
312	Sialadenitis <b>2021</b> , 48-63		
311	Childhood-onset of primary Sjgren's syndrome: phenotypic characterization at diagnosis of 158 children. <i>Rheumatology</i> , <b>2021</b> , 60, 4558-4567	3.9	4
310	Haemophagocytic syndrome and COVID-19. Clinical Rheumatology, <b>2021</b> , 40, 1233-1244	3.9	28
309	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	19
308	Therapeutic Recommendations for the Management of Older Adult Patients with Sjören's Syndrome. <i>Drugs and Aging</i> , <b>2021</b> , 38, 265-284	4.7	O

## (2020-2021)

307	Clinical characterization and outcomes of 85 patients with neurosarcoidosis. <i>Scientific Reports</i> , <b>2021</b> , 11, 13735	4.9	3
306	An update of targeted therapeutic options for primary Sj\( \begin{aligned} \text{gren syndrome: current status and future development. } \text{Expert Opinion on Pharmacotherapy, \begin{aligned} 2021, 22, 2359-2371 \end{aligned}	4	O
305	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 208-216	7.5	5
304	Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients. <i>Joint Bone Spine</i> , <b>2021</b> , 88, 105236	2.9	4
303	SARS-CoV-2 infection in patients with systemic autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 676-687	2.2	6
302	COVID-19 vaccination unveiling subclinical Sjgren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> ,	2.2	
301	Practical guidelines for the early diagnosis of Sjgren's syndrome in primary healthcare. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 197-205	2.2	1
300	Post-COVID-19 syndrome in patients with primary Sjਊren's syndrome after acute SARS-CoV-2 infection. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 57-65	2.2	2
299	COVID-19 vaccination unveiling subclinical Sj\(\bar{g}\)ren's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 228-229	2.2	1
298	Influence of the age at diagnosis in the disease expression of primary Sjgren syndrome. Analysis of 12,753 patients from the Sjgren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 166-174	2.2	O
297	Influence of the age at diagnosis in the disease expression of primary Sjgren syndrome. Analysis of 12,753 patients from the Sjgren Big Data Consortium <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 133, 166-174	2.2	
296	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
295	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 38	51.1	234
294	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
293	SAT0536 IMMUNE CHECKPOINT INHIBITOR THERAPY IN PATIENTS WITH PREEXISTING SARCOIDOSIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1225.2-1226	2.4	O
292	Granulocytes: Neutrophils, Basophils, Eosinophils <b>2020</b> , 243-262		1
291	EULAR recommendations for the management of Sj\u00e4ren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 3-18	2.4	139
<b>29</b> 0	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1800-1808	4.7	7

289	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
288	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15
287	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjgren's syndrome. <i>Rheumatology</i> , <b>2020</b> , 59, 2350-2359	3.9	24
286	The prevalence of 78 autoimmune diseases in Catalonia (MASCAT-PADRIS Big Data Project).  Autoimmunity Reviews, <b>2020</b> , 19, 102448	13.6	9
285	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
284	Weight of salivary gland ultrasonography compared to other items of the 2016 ACR/EULAR classification criteria for Primary Sjgren's syndrome. <i>Journal of Internal Medicine</i> , <b>2020</b> , 287, 180-188	10.8	26
283	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 67-77	9.5	18
282	Autoimmune congenital heart block and primary Sjören's syndrome: characterisation and outcomes of 49 cases. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 95-102	2.2	2
281	Systemic phenotype related to primary Sjਊren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 85-94	2.2	1
280	Systemic phenotype of sarcoidosis associated with radiological stages. Analysis of 1230 patients. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 69, 77-85	3.9	9
279	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 492-500	4.1	7
278	Geoepidemiology of Sarcoidosis <b>2019</b> , 1-21		O
277	Prognostic markers of lymphoma development in primary Sjören syndrome. <i>Lupus</i> , <b>2019</b> , 28, 923-936	2.6	28
276	How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants. <i>Lung</i> , <b>2019</b> , 197, 427-436	2.9	13
275	Synthetic pharmacotherapy for pulmonary sarcoidosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 1397-1404	4	4
274	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15
273	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
272	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46

271	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjigren's syndrome. <i>RMD Open</i> , <b>2019</b> , 5, e001064	5.9	24
270	THU0628 IMMUNE-RELATED ADVERSE EVENTS INDUCED BY CANCER IMMUNOTHERAPIES. BIG DATA ANALYSIS OF 13,051 CASES (IMMUNOCANCER INTERNATIONAL REGISTRY) <b>2019</b> ,		2
269	Sarcoidosis Involving the Gastrointestinal Tract: Diagnostic and Therapeutic Management. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1238-1247	0.7	22
268	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
267	Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 391-405	5.1	28
266	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 281-289	9.5	31
265	Systemic manifestations of primary Sj\( \textit{g}\)ren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 97-106	2.2	4
264	Sicca/Sjgren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 118, 114-122	2.2	16
263	Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 1052-1064	2.2	13
262	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , <b>2018</b> , 57, 677-687	3.9	20
261	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1478-1487	4.7	36
260	Cytokines as therapeutic targets in primary Sj\u00e4ren syndrome. <i>Pharmacology &amp; Therapeutics</i> , <b>2018</b> , 184, 81-97	13.9	15
259	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , <b>2018</b> , 4, 11	51.1	76
258	Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , <b>2018</b> , 2, 267-276	3.1	17
257	The Burden of Comorbidity and Complexity in Sarcoidosis: Impact of Associated Chronic Diseases. <i>Lung</i> , <b>2018</b> , 196, 239-248	2.9	28
256	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1294-1302	4.7	13
255	How immunological profile drives clinical phenotype of primary Sjgren's syndrome at diagnosis: analysis of 10,500 patients (Sjgren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 102-112	2.2	34
254	Phenotyping Sjgren's syndrome: towards a personalised management of the disease. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 198-209	2.2	12

253	Severe, life-threatening phenotype of primary Sjÿren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 121-129	2.2	20
252	Cardiovascular Involvement in Primary Sjgren's Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 14, 427-441	0.3	O
251	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. <i>Lupus</i> , <b>2017</b> , 26, 1051-1059	2.6	37
250	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1282-1299	13.4	58
249	Influence of geolocation and ethnicity on the phenotypic expression of primary Sj\u00dfren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sj\u00e4ren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1042-1050	2.4	73
248	Characterization and risk estimate of cancer in patients with primary Sjgren syndrome. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 90	22.4	72
247	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 523-541	13.6	66
246	Abdominal aortic aneurysm screening program using hand-held ultrasound in primary healthcare. <i>PLoS ONE</i> , <b>2017</b> , 12, e0176877	3.7	21
245	Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 1255-1271	4.1	72
244	Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1085-1101	3.8	6
243	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 575-583.e1	6.9	75
242	Primary Biliary Cholangitis. Handbook of Systemic Autoimmune Diseases, 2017, 13, 83-101	0.3	
241	Extrahepatic Manifestations in Patients With Chronic Hepatitis C Virus Infection. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 13, 173-202	0.3	
240	Digestive Involvement in Primary Sjgren's Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 271-292	0.3	2
239	IgG4-Related Disease: Gastrointestinal Involvement. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 13, 399-410	0.3	
238	Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. <i>Revista Espatola De Sanidad Penitenciaria</i> , <b>2017</b> , 19, 87-97	0.4	9
237	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
236	Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 391-9	5.3	40

## (2016-2016)

235	IgG4-related disease: Advances in the diagnosis and treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2016</b> , 30, 261-278	5.3	49
234	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 1145-1160	13.6	69
233	Treating the Underlying Pathophysiology of Primary Sjigren Syndrome: Recent Advances and Future Prospects. <i>Drugs</i> , <b>2016</b> , 76, 1601-1623	12.1	12
232	Sarcoidosis: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2431-2448	4	26
231	Sjgren syndrome. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16047	51.1	267
230	THU0352 Worldwide Heterogeneous Diagnostic Approach To Primary Sjören Syndrome in 8315 Patients (EULAR-SS Task Force Big Data Sjören Project). <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 314.2-315	2.4	
229	Systemic activity and mortality in primary Sj\( \textit{g}\)ren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 348-55	2.4	102
228	Defining disease activity states and clinically meaningful improvement in primary Sjgren's syndrome with EULAR primary Sjgren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 382-9	2.4	144
227	Autoimmune congenital heart block: complex and unusual situations. <i>Lupus</i> , <b>2016</b> , 25, 116-28	2.6	32
226	Early diagnosis of primary Sj\u00e4ren's syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, <b>2016</b> , 12, 137-56	5.1	83
225	Systemic Therapy of Sjgren Syndrome. Rare Diseases of the Immune System, <b>2016</b> , 383-398	0.2	1
224	Complexity, comorbidity, and health care costs associated with chronic widespread pain in primary care. <i>Pain</i> , <b>2016</b> , 157, 818-826	8	26
223	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27
222	Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000143	4.6	40
221	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000163	4.6	34
220	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1945-1950	2.4	41
219	Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjgren syndrome: analysis of 515 patients. <i>Rheumatology</i> , <b>2016</b> , 55, 1443-51	3.9	41
218	Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 380-8	2.2	22

217	Characterization of systemic disease in primary Sjਊren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , <b>2015</b> , 54, 2230-8	3.9	150
216	Diagnostic Approach to the Complexity of IgG4-Related Disease. <i>Mayo Clinic Proceedings</i> , <b>2015</b> , 90, 927	-3694	119
215	How are we treating our systemic patients with primary Sj\( \)gren syndrome? Analysis of 1120 patients. <i>International Immunopharmacology</i> , <b>2015</b> , 27, 194-9	5.8	17
214	The clinical spectrum of autoimmune congenital heart block. <i>Nature Reviews Rheumatology</i> , <b>2015</b> , 11, 301-12	8.1	140
213	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1837-47	9.5	77
212	Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 128-35	4.7	31
211	Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 670-9	13.6	96
210	OP0274 Cryoglobulinemic Vasculitis and Primary sjਊren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins.  Annals of the Rheumatic Diseases, 2015, 74, 175.3-176	2.4	
209	How hepatitis C virus modifies the immunological profile of Sjgren syndrome: analysis of 783 patients. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 250	5.7	24
208	Validation of EULAR primary Sjgren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 859-66	2.4	138
207	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1530-6	2.4	51
206	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
205	THU0408 How we are Treating Our Systemic Patients with Primary Sjgren Syndrome? Analysis of 1120 Patients (GEAS-SS Spanish Registry). <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 344.2-344	2.4	
204	EULAR Sjgren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , <b>2015</b> , 1, e000022	5.9	150
203	Treatment of cryoglobulinemic vasculitis associated with hepatitis C virus infection. <i>Medicina Claica (English Edition)</i> , <b>2015</b> , 144, 410-417	0.3	
202	Etiopathogenic role of surfactant protein d in the clinical and immunological expression of primary Sjgren syndrome. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 111-8	4.1	5
201	Outcome measures for primary Sjgren's syndrome: a comprehensive review. <i>Journal of Autoimmunity</i> , <b>2014</b> , 51, 51-6	15.5	55
200	Granulocytes <b>2014</b> , 201-215		3

199	Adult haemophagocytic syndrome. Lancet, The, 2014, 383, 1503-1516	40	698
198	The clinical spectrum of IgG4-related disease. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 1203-10	13.6	192
197	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , <b>2014</b> , 53, 2209-1	1 <b>3</b> 3.9	55
196	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 875-80	4.1	17
195	THU0396 Igg4-Related Disease or Primary Sjogren Syndrome? Organ-Specific Involvement and Immunological Profile Are Clues in Differentiating Two Diseases with A Common Clinical Presentation. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 318.3-319	2.4	
194	OP0217 Defining Disease Activity Sates and Minimal Clinically Important Improvement (MCII) with the EULAR Primary Sj&ren's Syndrome Disease Activity Index (ESSDAI). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 144.2-145	2.4	9
193	Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responses. <i>PLoS ONE</i> , <b>2014</b> , 9, e84895	3.7	13
192	Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). <i>Rheumatology</i> , <b>2014</b> , 53, 321-31	3.9	125
191	SAT0206 Minimally-Invasive Technique for the Biopsy of Minor Salivary Glands: Searching for Systemic Infiltrative Diseases in Patients Presenting with SICCA Symptoms. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 664.2-664	2.4	1
190	Advances in the understanding and treatment of systemic complications in Sjgren's syndrome. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 520-7	5.3	50
189	Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases. <i>Lupus</i> , <b>2014</b> , 23, 166-75	2.6	27
188	Targeting B Cells in Other Systemic Autoimmune Diseases. <i>Milestones in Drug Therapy</i> , <b>2014</b> , 247-258		
187	Systemic Lupus Erythematosus: Indirect B-Cell Blocking. <i>Milestones in Drug Therapy</i> , <b>2014</b> , 79-95		
186	Factors influencing dry mouth in patients with primary Sj\( \)gren syndrome: usefulness of the ESSPRI index. Oral Health and Dental Management, 2014, 13, 402-7	O	6
185	Primary Sjgren syndrome: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 279-89	4	38
184	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2887-97		65
183	Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 476-8	2.4	73
182	Is it time for biosimilars in autoimmune diseases?. Autoimmunity Reviews, 2013, 12, 954-7	13.6	20

181	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1308-14	2.4	65
180	Biologics-induced autoimmune diseases. <i>Current Opinion in Rheumatology</i> , <b>2013</b> , 25, 56-64	5.3	113
179	THU0283 Two Year Follow-Up on Biologics Use in 13 Centers - Data from the International Registry for Biologics in SLE (IRBIS). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A261.3-A262	2.4	
178	SAT0175 Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A640.2-A641	2.4	
177	Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients. <i>Medicine (United States)</i> , <b>2013</b> , 92, 273-284	1.8	53
176	Diagnosis of Liver Involvement in Primary Sjgren Syndrome. <i>Journal of Clinical and Translational Hepatology</i> , <b>2013</b> , 1, 94-102	5.2	15
175	Cryoglobulinemic disease. <i>Oncology</i> , <b>2013</b> , 27, 1098-1105, 1110-6	1.8	13
174	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 357-64	13.6	176
173	B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. <i>Autoimmunity Reviews</i> , <b>2012</b> , 11, 646-52	13.6	32
172	Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. <i>Seminars in Arthritis and Rheumatism</i> , <b>2012</b> , 41, 789-800	5.3	69
171	The cryoglobulinaemias. Lancet, The, 2012, 379, 348-60	40	358
170	Topical and systemic medications for the treatment of primary Sjgren's syndrome. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 399-411	8.1	123
169	Primary Sjogren syndrome. <i>BMJ, The</i> , <b>2012</b> , 344, e3821	5.9	166
168	B-cell-depleting therapy in systemic lupus erythematosus. <i>American Journal of Medicine</i> , <b>2012</b> , 125, 327	-364	58
167	The DWEYS peptide in systemic lupus erythematosus. <i>Trends in Molecular Medicine</i> , <b>2012</b> , 18, 215-23	11.5	13
166	Monoclonal gammopathy related to Sjgren syndrome: a key marker of disease prognosis and outcomes. <i>Journal of Autoimmunity</i> , <b>2012</b> , 39, 43-8	15.5	55
165	Outcome measures for primary Sjgren's syndrome. <i>Journal of Autoimmunity</i> , <b>2012</b> , 39, 97-102	15.5	40
164	Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions. <i>Clinical and Developmental Immunology</i> , <b>2012</b> , 2012, 974648		32

163	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.4	115
162	Punctal occlusion in Sjgren's syndrome needs clarification. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 752-	7821	
161	White matter abnormalities in primary Sjgren syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2012</b> , 105, 433-43	2.7	23
160	Rituximab in SLE <b>2012</b> , 32-41		
159	Biologics use in sle in 23 centers Idata from the international registry for biologics in SLE. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A9.1-A9	2.4	1
158	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, S48-52	2.2	25
157	Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjgren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 686-92	2.2	27
156	Monoclonal antibody therapy-associated neurological disorders. <i>Nature Reviews Neurology</i> , <b>2011</b> , 7, 16.	5 <i>-17</i> 52	95
155	EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 968-72	2.4	264
154	Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R112	5.7	46
153	Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. <i>American Journal of Medicine</i> , <b>2011</b> , 124, 386-94	2.4	45
152	Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 41, 256-64	5.3	190
151	Rituximab therapy in lupus nephritis: current clinical evidence. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2011</b> , 40, 159-69	12.3	31
150	Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1726-32	2.4	111
149	Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. <i>Medicine (United States)</i> , <b>2011</b> , 90, 359-371	1.8	203
148	SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 961-7	2.4	39
147	Other Biological Therapies in Primary Sjören Syndrome <b>2011</b> , 589-598		
146	Basophils, IgE, and autoantibody-mediated kidney disease. <i>Journal of Immunology</i> , <b>2011</b> , 186, 6083-90	5.3	14

145	Therapeutic targeting of B cells for rheumatic autoimmune diseases. <i>Pharmacological Reviews</i> , <b>2011</b> , 63, 127-56	22.5	80
144	Gastrointestinal Involvement in Primary Sjਊren⊠ Syndrome <b>2011</b> , 227-235		
143	Primary Sjgren Syndrome in Primary Health Care <b>2011</b> , 501-514		
142	Primary Sjgren Syndrome and Viruses <b>2011</b> , 55-66		
141	Myths, Pearls, and Tips Regarding Sjgren Syndrome <b>2011</b> , 15-34		
140	Life-Threatening Cryoglobulinemia <b>2011</b> , 133-162		
139	Laboratory Abnormalities in Primary Sjigren Syndrome <b>2011</b> , 347-366		Ο
138	Immunological Tests in Primary Sjgren Syndrome <b>2011</b> , 401-416		1
137	Sjgren Syndrome: Beyond Sicca Involvement <b>2011</b> , 45-65		6
136	Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. <i>British Journal of Dermatology</i> , <b>2010</b> , 162, 91-101	4	77
135	Cutaneous lupus erythematosus: clinical and immunological study of 308 patients stratified by gender. <i>Clinical and Experimental Dermatology</i> , <b>2010</b> , 35, 729-35	1.8	19
134	Cardiovascular risk factors in primary Sjgren's syndrome: a case-control study in 624 patients. <i>Lupus</i> , <b>2010</b> , 19, 941-8	2.6	58
133	Treatment of primary Sjgren syndrome: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 452-60	27.4	240
132	Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 529-35	2.4	184
131	Targeted therapy for systemic sclerosis: how close are we?. <i>Nature Reviews Rheumatology</i> , <b>2010</b> , 6, 269-	<b>788</b> 1	18
130	Clinical and prognostic significance of parotid scintigraphy in 405 patients with primary Sjogren's syndrome. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 585-90	4.1	39
129	Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. <i>Medicine (United States)</i> , <b>2010</b> , 89, 300-307	1.8	41
128	Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?. <i>Nature Reviews Rheumatology</i> , <b>2010</b> , 6, 618-20	8.1	6

## (2008-2010)

127	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 20-8	2.4	645
126	Systematic review on the use of adalimumab in autoinmune. Efficacy and safety in 54 patients. <i>Reumatologd Claica (English Edition)</i> , <b>2010</b> , 6, 121-127	0.1	
125	Treatment of Primary Sjgren Syndrome: A Systematic Review. Yearbook of Medicine, 2010, 2010, 43-44		
124	Sjgren syndrome or sjgren disease? The histological and immunological bias caused by the 2002 criteria. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2010</b> , 38, 178-85	12.3	28
123	Autoimmune diseases induced by biological agents: a double-edged sword?. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 188-93	13.6	245
122	Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , <b>2010</b> , 28, 468-76	2.2	81
121	Bronchiectasis in primary Sjgren's syndrome: prevalence and clinical significance. <i>Clinical and Experimental Rheumatology</i> , <b>2010</b> , 28, 647-53	2.2	25
120	Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjgren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2009</b> , 38, 389-95	5.3	28
119	Chronic hepatitis B virus infection in Sjgren's syndrome. Prevalence and clinical significance in 603 patients. <i>Autoimmunity Reviews</i> , <b>2009</b> , 8, 616-20	13.6	27
118	Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1281-2		42
118		4.1	107
	Arthritis and Rheumatism, 2009, 61, 1281-2  Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020	4.1	
117	Arthritis and Rheumatism, 2009, 61, 1281-2  Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). Journal of Rheumatology, 2009, 36, 1442-8  Classification of fibromyalgia. A systematic review of the literature. Reumatologa Claica (English		
117 116	Arthritis and Rheumatism, 2009, 61, 1281-2  Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). Journal of Rheumatology, 2009, 36, 1442-8  Classification of fibromyalgia. A systematic review of the literature. Reumatologa Claica (English Edition), 2009, 5, 55-62  Extrahepatic manifestations in patients with chronic infections due to the hepatitis C virus.	0.1	
117 116 115	Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). Journal of Rheumatology, 2009, 36, 1442-8  Classification of fibromyalgia. A systematic review of the literature. Reumatologa Claica (English Edition), 2009, 5, 55-62  Extrahepatic manifestations in patients with chronic infections due to the hepatitis C virus. Reumatologa Claica (English Edition), 2009, 5, 71-75  Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus	0.1	107
117 116 115	Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). Journal of Rheumatology, 2009, 36, 1442-8  Classification of fibromyalgia. A systematic review of the literature. Reumatologa Claica (English Edition), 2009, 5, 55-62  Extrahepatic manifestations in patients with chronic infections due to the hepatitis C virus. Reumatologa Claica (English Edition), 2009, 5, 71-75  Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus, 2009, 18, 767-76  Mannose-binding lectin-low genotypes are associated with milder systemic and immunological	0.1	107
117 116 115 114 113	Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). Journal of Rheumatology, 2009, 36, 1442-8  Classification of fibromyalgia. A systematic review of the literature. Reumatologia Claica (English Edition), 2009, 5, 55-62  Extrahepatic manifestations in patients with chronic infections due to the hepatitis C virus. Reumatologia Claica (English Edition), 2009, 5, 71-75  Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus, 2009, 18, 767-76  Mannose-binding lectin-low genotypes are associated with milder systemic and immunological disease expression in primary Sjigren's syndrome. Rheumatology, 2009, 48, 65-9  Clinical guidelines for the management of acute viral infections in patients with systemic lupus	0.1 0.1 2.6 3.9	107 237 15

109	Chapter 7 Digestive Involvement in Primary Sjören's Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 8, 71-81	0.3	
108	Chapter 16 Extrahepatic Manifestations in Patients with Chronic Hepatitis C Virus Infection. Handbook of Systemic Autoimmune Diseases, <b>2008</b> , 8, 209-304	0.3	1
107	Chapter 9 Adrenal Involvement in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 9, 95-101	0.3	
106	Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. <i>Lupus</i> , <b>2008</b> , 17, 281-8	2.6	120
105	Primary Sjgren syndrome in Spain: clinical and immunologic expression in 1010 patients. <i>Medicine</i> (United States), 2008, 87, 210-219	1.8	358
104	Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. <i>Medicine (United States)</i> , <b>2008</b> , 87, 311-318	1.8	107
103	Autoimmune diseases in the elderly: systemic lupus erythematosus and Sj\u00e4ren\u00b8 syndrome. <i>Aging Health</i> , <b>2008</b> , 4, 389-397		1
102	A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. <i>Medicine (United States)</i> , <b>2008</b> , 87, 345-364	1.8	112
101	Vasculitis induced by tumor necrosis factor-targeted therapies. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 442-8	4.9	48
100	Extrahepatic Manifestations in Patients with Chronic Hepatitis C Virus Infection 2008, 301-305		
99	Characterization of B cell lymphoma in patients with Sjgren's syndrome and hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 161-70		62
98	Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. <i>Journal of Viral Hepatitis</i> , <b>2007</b> , 14, 736-42	3.4	20
97	The overlap of Sjgren's syndrome with other systemic autoimmune diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2007</b> , 36, 246-55	5.3	96
96	Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. <i>Seminars in Arthritis and Rheumatism</i> , <b>2007</b> , 36, 287-96	5.3	54
95	Advances in lupus and Sj\(\bar{g}\)ren's syndrome: a tribute to Josep Font. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1108, 51-63	6.5	
94	Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"a tribute to the late Josep Font. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1108, 448-56	6.5	18
93	Thyroid disease in Sjgren's syndrome. <i>Clinical Rheumatology</i> , <b>2007</b> , 26, 1601-6	3.9	70
92	Lessons from diseases mimicking Sjgren's syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2007</b> , 32, 275-83	12.3	14

#### (2006-2007)

91	Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus. <i>Rheumatology</i> , <b>2007</b> , 46, 76-80	3.9	38
90	New approaches in Sjgren's syndrome therapy. Expert Review of Clinical Immunology, 2007, 3, 195-204	5.1	6
89	Emerging biological therapies in primary Sjogren's syndrome. Rheumatology, 2007, 46, 1389-96	3.9	39
88	Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. <i>Medicine (United States)</i> , <b>2007</b> , 86, 242-251	1.8	493
87	Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. <i>Rheumatology</i> , <b>2007</b> , 46, 1359-62	3.9	114
86	Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 740-6	2.4	72
85	High prevalence of serum metabolic alterations in primary Sj\( \begin{align*} \text{gren}'s syndrome: influence on clinical and immunological expression. \( \text{Journal of Rheumatology}, \text{2007}, 34, 754-61 \end{align*}	4.1	38
84	Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". <i>Autoimmunity Reviews</i> , <b>2006</b> , 5, 180-6	13.6	99
83	Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. <i>Autoimmunity Reviews</i> , <b>2006</b> , 6, 72-5	13.6	69
82	Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 35, 322-32	5.3	106
81	Atypical autoantibodies in patients with primary Sj\( \bar{g}\)ren syndrome: clinical characteristics and follow-up of 82 cases. Seminars in Arthritis and Rheumatism, 2006, 35, 312-21	5.3	84
80	Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 36, 189-96	5.3	78
79	Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2568-76		229
78	Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. <i>Medicine (United States)</i> , <b>2006</b> , 85, 95-104	1.8	140
77	The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2006</b> , 65, 81-6	2.4	48
76	Antiphospholipid syndrome and minimal change nephropathy. <i>Lupus</i> , <b>2006</b> , 15, 547-8	2.6	2
75	Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. <i>Lupus</i> , <b>2006</b> , 15, 584-9	2.6	151
74	Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjgren's syndrome: prevalence and clinical significance in 335 patients. <i>Clinical Rheumatology</i> , <b>2006</b> , 25, 341-6	3.9	7°

73	Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjgren's syndrome. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1593-9	4.1	25
72	Circulating monoclonal immunoglobulins in Sj\( \)gren syndrome: prevalence and clinical significance in 237 patients. <i>Medicine (United States)</i> , <b>2005</b> , 84, 90-97	1.8	35
71	Primary Sjਊren's syndrome: current and emergent aetiopathogenic concepts. <i>Rheumatology</i> , <b>2005</b> , 44, 1354-67	3.9	84
70	Primary Sjਊren's syndrome: new clinical and therapeutic concepts. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 347-54	2.4	183
69	Sjgren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. <i>Medicine</i> (United States), <b>2005</b> , 84, 81-89	1.8	138
68	Extrahepatic manifestations in patients with chronic hepatitis C virus infection. <i>Current Opinion in Internal Medicine</i> , <b>2005</b> , 17, 447-55		21
67	Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. <i>Journal of Internal Medicine</i> , <b>2005</b> , 257, 549-57	10.8	61
66	Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. <i>Journal of Viral Hepatitis</i> , <b>2005</b> , 12, 648-54	3.4	22
65	Hepatitis C virus, Sjgren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 8-15	13.6	76
64	Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 89-94		136
63	Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 95-9		47
63		2.6	18
	of 30 patients. British Journal of Rheumatology, <b>2005</b> , 44, 95-9	2.6	
62	of 30 patients. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 95-9  Mycophenolate mofetil in patients with hepatitis C virus infection. <i>Lupus</i> , <b>2005</b> , 14, 64-72		18
62	of 30 patients. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 95-9  Mycophenolate mofetil in patients with hepatitis C virus infection. <i>Lupus</i> , <b>2005</b> , 14, 64-72  Mycophenolate mofetil in patients with hepatitis C virus infection. <i>Lupus</i> , <b>2005</b> , 14 Suppl 1, s64-72  Validation of the preliminary criteria for the classification of catastrophic antiphospholipid	2.6	18
62 61 60	of 30 patients. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 95-9  Mycophenolate mofetil in patients with hepatitis C virus infection. <i>Lupus</i> , <b>2005</b> , 14, 64-72  Mycophenolate mofetil in patients with hepatitis C virus infection. <i>Lupus</i> , <b>2005</b> , 14 Suppl 1, s64-72  Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 1205-9  Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and	2.6	18 25 155
62 61 60 59	of 30 patients. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 95-9  Mycophenolate mofetil in patients with hepatitis C virus infection. <i>Lupus</i> , <b>2005</b> , 14, 64-72  Mycophenolate mofetil in patients with hepatitis C virus infection. <i>Lupus</i> , <b>2005</b> , 14 Suppl 1, s64-72  Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 1205-9  Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 943-6  Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. <i>Medicine (United</i> )	2.6 2.4 2.4	18 25 155 60

55	Coeliac disease associated with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2004</b> , 63, 104-5	2.4	17
54	Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38, 1009-16	11.6	63
53	Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. <i>Annals of the Rheumatic Diseases</i> , <b>2004</b> , 63, 1312-7	2.4	127
52	Treatment of B-cell lymphoma with rituximab in two patients with Sjgren's syndrome associated with hepatitis C virus infection. <i>Lupus</i> , <b>2004</b> , 13, 969-71	2.6	29
51	Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. <i>Seminars in Arthritis and Rheumatism</i> , <b>2004</b> , 33, 217-30	5.3	114
50	Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia. <i>Autoimmunity Reviews</i> , <b>2004</b> , 3, 376-82	13.6	22
49	Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. <i>Lupus</i> , <b>2004</b> , 13, 777-83	2.6	54
48	Sarcoidosis or Sjgren syndrome? Clues to defining mimicry or coexistence in 59 cases. <i>Medicine</i> (United States), <b>2004</b> , 83, 85-95	1.8	53
47	Cutaneous vasculitis in primary Sjgren syndrome: classification and clinical significance of 52 patients. <i>Medicine (United States)</i> , <b>2004</b> , 83, 96-106	1.8	147
46	Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 495-9	4.1	38
45	Interleukin-4 receptor alpha polymorphisms in primary Sjgren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2004</b> , 22, 374	2.2	5
44	Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. <i>British Journal of Rheumatology</i> , <b>2003</b> , 42, 818-28		29
43	Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. <i>Medicine (United States)</i> , <b>2003</b> , 82, 87-96	1.8	76
42	Hematologic malignancies in patients with cryoglobulinemia: association with autoimmune and chronic viral diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2003</b> , 33, 19-28	5.3	34
41	Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. <i>Lupus</i> , <b>2003</b> , 12, 341-55	2.6	92
40	Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. <i>Annals of the Rheumatic Diseases</i> , <b>2003</b> , 62, 431-4	2.4	84
39	Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. <i>Medicine (United States)</i> , <b>2003</b> , 82, 299-308	1.8	863
38	Pure sensory neuropathy in primary Sj\( \begin{aligned} \text{Tensor} \) syndrome. Longterm prospective followup and review of the literature. Journal of Rheumatology, \( 2003 \), 30, 1552-7	4.1	44

37	Th1/Th2 cytokine imbalance in patients with Sjgren syndrome secondary to hepatitis C virus infection. <i>Seminars in Arthritis and Rheumatism</i> , <b>2002</b> , 32, 56-63	5.3	31
36	The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjgren's syndrome. <i>British Journal of Rheumatology</i> , <b>2002</b> , 41, 1025-30		44
35	Primary Sjigren syndrome: hematologic patterns of disease expression. <i>Medicine (United States)</i> , <b>2002</b> , 81, 281-92	1.8	93
34	Primary Sjgren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. <i>Medicine (United States)</i> , <b>2002</b> , 81, 270-80	1.8	279
33	Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjgren's syndrome. Correlation with clinical, immunological and histological features. <i>British Journal of Rheumatology</i> , <b>2002</b> , 41, 670-5		24
32	Viral etiopathogenesis of Sjgren's syndrome: role of the hepatitis C virus. <i>Autoimmunity Reviews</i> , <b>2002</b> , 1, 238-43	13.6	30
31	Manifestaciones clūicas e inmunolūjicas asociadas a la infecciū crūica por el virus de la hepatitis C. <i>Revista Clinica Espanola</i> , <b>2002</b> , 202, 224-232	0.7	1
30	Raynaud's phenomenon in primary Sjgren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 726-30	4.1	47
29	Low values of creatine kinase in systemic lupus erythematosus. Clinical significance in 300 patients. <i>Clinical and Experimental Rheumatology</i> , <b>2002</b> , 20, 837-40	2.2	4
28	Lessons from the "Euro-Lupus Cohort". <i>Annales De Mdecine Interne</i> , <b>2002</b> , 153, 530-6		10
28	Lessons from the "Euro-Lupus Cohort". <i>Annales De Mdecine Interne</i> , <b>2002</b> , 153, 530-6  Hepatitis C virus infection mimicking primary Sj\(\frac{1}{2}\)ren syndrome. A clinical and immunologic description of 35 cases. <i>Medicine (United States)</i> , <b>2001</b> , 80, 1-8	1.8	10
	Hepatitis C virus infection mimicking primary Sjgren syndrome. A clinical and immunologic	1.8 5.3	
27	Hepatitis C virus infection mimicking primary Sj\( \text{gren syndrome}. A clinical and immunologic description of 35 cases. \( Medicine \) (United States), \( 2001, 80, 1-8 \)  Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a		117
27 26	Hepatitis C virus infection mimicking primary Sj\(\frac{1}{2}\)ren syndrome. A clinical and immunologic description of 35 cases. <i>Medicine (United States)</i> , <b>2001</b> , 80, 1-8  Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>2001</b> , 30, 366-73  Cardiovascular risk factors and the long-term outcome of lupus nephritis. <i>QJM - Monthly Journal of</i>	5.3	117 69
27 26 25	Hepatitis C virus infection mimicking primary Sj\(\frac{1}{2}\)ren syndrome. A clinical and immunologic description of 35 cases. Medicine (United States), 2001, 80, 1-8  Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Seminars in Arthritis and Rheumatism, 2001, 30, 366-73  Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 19-26  Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients	5.3	<ul><li>117</li><li>69</li><li>54</li></ul>
27 26 25 24	Hepatitis C virus infection mimicking primary Sj\u00e4ren syndrome. A clinical and immunologic description of 35 cases. <i>Medicine (United States)</i> , 2001, 80, 1-8  Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2001, 30, 366-73  Cardiovascular risk factors and the long-term outcome of lupus nephritis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2001, 94, 19-26  Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. <i>Medicine (United States)</i> , 2001, 80, 252-62  Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.	5.3 2.7 1.8	<ul><li>117</li><li>69</li><li>54</li><li>199</li></ul>
27 26 25 24 23	Hepatitis C virus infection mimicking primary Sj\(\frac{0}{0}\) ren syndrome. A clinical and immunologic description of 35 cases. Medicine (United States), 2001, 80, 1-8  Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Seminars in Arthritis and Rheumatism, 2001, 30, 366-73  Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 19-26  Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (United States), 2001, 80, 252-62  Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (United States), 2001, 80, 355-77  High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary	5.3 2.7 1.8	<ul><li>117</li><li>69</li><li>54</li><li>199</li><li>281</li></ul>

#### (1998-2000)

19	Thyroid disease in primary Sjgren syndrome. Study in a series of 160 patients. <i>Medicine (United States)</i> , <b>2000</b> , 79, 103-8	1.8	56	
18	Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 2801-6		78	
17	Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE). <i>Clinical and Experimental Immunology</i> , <b>2000</b> , 119, 169-74	6.2	18	
16	Cytopenia and past human parvovirus B19 infection in patients with primary Sjgren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2000</b> , 29, 373-8	5.3	43	
15	Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. <i>Lupus</i> , <b>2000</b> , 9, 584-8	2.6	49	
14	Circulating concentrations of soluble L-selectin (CD62L) in patients with primary Sjgren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2000</b> , 59, 297-9	2.4	11	
13	Primary Sjgren's syndrome in men: clinical and immunological characteristics. <i>Lupus</i> , <b>2000</b> , 9, 61-4	2.6	33	
12	Splenectomy for refractory Evans' syndrome associated with antiphospholipid antibodies: report of two cases. <i>Annals of the Rheumatic Diseases</i> , <b>2000</b> , 59, 920-3	2.4	21	
11	Mixed cryoglobulinemia: new concepts. <i>Lupus</i> , <b>2000</b> , 9, 83-91	2.6	57	
10	Catastrophic antiphospholipid syndrome: clinical description and triggering factors in 8 patients. <i>Journal of Rheumatology</i> , <b>2000</b> , 27, 238-40	4.1	31	
9	Primary Sjÿren's syndrome in the elderly: clinical and immunological characteristics. <i>Lupus</i> , <b>1999</b> , 8, 20-3	2.6	50	
8	Nodular regenerative hyperplasia of the liver and antiphospholipid antibodies: report of two cases and review of the literature. <i>Lupus</i> , <b>1999</b> , 8, 160-3	2.6	38	
7	Sjਊren's syndrome and hepatitis C virus. <i>Clinical Rheumatology</i> , <b>1999</b> , 18, 93-100	3.9	44	
6	Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>1999</b> , 28, 326-32	5.3	72	
5	Cryoglobulinemia in primary Sjਊren's syndrome: prevalence and clinical characteristics in a series of 115 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>1998</b> , 28, 200-5	5.3	90	
4	Hepatitis G virus infection in primary Sj\u00dfren's syndrome: analysis in a series of 100 patients. <i>Annals of the Rheumatic Diseases</i> , <b>1998</b> , 57, 42-4	2.4	11	
3	Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. <i>Annals of the Rheumatic Diseases</i> , <b>1998</b> , 57, 456-9	2.4	194	
2	Antineutrophil cytoplasmic antibodies in primary Sj\( \bar{g}\)ren's syndrome: prevalence and clinical significance. British Journal of Rheumatology, 1998, 37, 1287-91		49	

Young onset of primary Sjgren's syndrome: clinical and immunological characteristics. *Lupus*, **1998**, 7, 202-6

2.6 66